Key Points
- CFO Kelly Gold purchased 10,000 CAMP4 Therapeutics shares at an average price of $3.96, investing $39,600 and bringing her total holdings to 10,000 shares. She also bought 6,551 shares earlier in August at $1.65 each.
- CAMP4 opened at $3.80, with a market capitalization of approximately $238.45 million, and trades well below its 52-week high of $7.75. The company reported a quarterly loss of $0.58 per share, significantly missing the $0.24 consensus estimate, on revenue of $1.78 million.
- Analyst sentiment is broadly positive, with seven Buy ratings and a consensus target price of $9.56, although ratings range from Sell to bullish targets as high as $15.00. Several institutional investors have also recently established significant positions in the company.
CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) CFO Kelly Gold purchased 10,000 shares of the business's stock in a transaction on Monday, August 31st. The stock was bought at an average cost of $3.96 per share, with a total value of $39,600.00. Following the purchase, the chief financial officer owned 10,000 shares in the company, valued at approximately $39,600. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Kelly Gold also recently made the following trade(s):
- On Monday, August 3rd, Kelly Gold purchased 6,551 shares of CAMP4 Therapeutics stock. The stock was bought at an average cost of $1.65 per share, for a total transaction of $10,809.15.
CAMP4 Therapeutics Stock Performance
CAMP4 Therapeutics stock opened at $3.80 on Thursday. The firm's fifty day moving average price is $4.11 and its 200-day moving average price is $4.34. The stock has a market cap of $238.45 million, a P/E ratio of -1.64 and a beta of 0.27. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.41 and a fifty-two week high of $7.75.
CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The company had revenue of $1.78 million for the quarter. On average, analysts predict that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current year.
Institutional Trading of CAMP4 Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Jupiter Topco LLC purchased a new stake in CAMP4 Therapeutics during the second quarter valued at about $27,581,000. 5AM Venture Management LLC bought a new position in shares of CAMP4 Therapeutics during the second quarter valued at about $25,647,928. Vivo Capital LLC purchased a new position in shares of CAMP4 Therapeutics in the third quarter worth about $11,765,000. Balyasny Asset Management L.P. purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter worth about $14,938,000. Finally, Trails Edge Capital Partners LP bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $8,446,935.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the company. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, June 10th. Weiss Ratings raised CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 14th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Zacks Research raised CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, August 17th. Finally, UBS Group set a $15.00 target price on CAMP4 Therapeutics in a research note on Friday, August 14th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, CAMP4 Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $9.56.
Read Our Latest Stock Analysis on CAMP4 Therapeutics
About CAMP4 Therapeutics
(
Get Free Report)
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
